Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech leadership pharma Research & Development research-development

	Profile	Recent Articles on Subject
1	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 17 days ago Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 4 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 4 months ago With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble - 4 months ago Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps - about 1 year ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma’s forecast for 2025: Sowing seeds of a rebound - 23 days ago 3 closely watched drugs that failed in the clinic - 2 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 4 months ago BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s - 5 months ago An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 5 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 9 months ago Where competition is heating up in pharma - 9 months ago PharmaVoice 100s: Entrepreneurs - over 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly - about 2 months ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - about 2 months ago STAT+: Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more - 3 months ago STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 4 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 4 months ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 9 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 11 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 11 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 11 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - about 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - about 1 year ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - about 1 year ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - about 1 year ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - about 1 year ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade - about 1 year ago STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - over 1 year ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - over 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - over 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - over 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - over 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - over 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - over 1 year ago
5	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Poolbeg Pharma presents positive results for POLB 001 - 3 months ago Poolbeg’s cytokine release syndrome drug shows potential - about 1 year ago Kanabo and City Dock Pharmacy team up - about 1 year ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 3 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 6 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 7 months ago After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners - 8 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 6 months ago STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease - about 1 year ago
8	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 6 months ago
9	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 10 months ago STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk - 12 months ago
10	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells - 11 months ago STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 12 months ago

Journalists covering Poolbeg Pharma